Warner Chilcott

Announcement Under Irish Takeover Rules Revision to Relevant Securities in Issue

DUBLIN, Ireland, May 20, 2013 (GLOBE NEWSWIRE) -- In accordance with Rule 2.10 of the Irish Takeover Rules, Warner Chilcott plc (Nasdaq:WCRX) (the "

Warner Chilcott

Announcement Under Irish Takeover Rules Relevant Securities in Issue

DUBLIN, Ireland, May 13, 2013 (GLOBE NEWSWIRE) -- In accordance with Rule 2.10 of the Irish Takeover Rules, Warner Chilcott plc (Nasdaq:WCRX) (the "

Warner Chilcott

Warner Chilcott Statement Regarding Market Speculation

DUBLIN, Ireland, May 10, 2013 (GLOBE NEWSWIRE) -- Further to media speculation, the Board of Warner Chilcott plc (Nasdaq:WCRX) confirmed today that the Company is engaged in preliminary discussions with Actavis, Inc. regarding a potential business combination transaction. These discussions are at a preliminary stage and may or may not lead to an offer for the Company. The Company does not intend to comment further on market speculation or disclose any developments unless and until it otherwise deems further disclosure is appropriate or required.

Warner Chilcott

Warner Chilcott Reports Operating Results for the Quarter Ended March 31, 2013

DUBLIN, Ireland, May 10, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced its results for the quarter ended March 31, 2013.

Warner Chilcott

Warner Chilcott Announces FDA Approval of New Oral Contraceptive

DUBLIN, Ireland, May 9, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that the United States Food and Drug Administration (FDA) has approved a new oral contraceptive, norethindrone acetate and ethinyl estradiol chewable tablets and ferrous fumarate tablets, for the prevention of pregnancy. This product does not currently have a brand name. The Company anticipates that it will commercially launch the product in early August 2013.

Warner Chilcott

Warner Chilcott Declares Semi-Annual Cash Dividend of $0.25 Per Share

DUBLIN, Ireland, May 7, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that its Board of Directors declared a semi-annual cash dividend in the amount of $0.25 per share, payable June 14, 2013, to shareholders of record at the close of business on May 31, 2013.

Warner Chilcott

Warner Chilcott Announces Changes to Board of Directors

DUBLIN, Ireland, May 2, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that its Board of Directors has voted unanimously to appoint Paul Herendeen, the Company's Executive Vice President and Chief Financial Officer, to the Company's Board effective as of May 2, 2013. Mr. Herendeen will continue to serve as Executive Vice President and Chief Financial Officer of the Company.

Warner Chilcott

Warner Chilcott Announces Earnings Release Date and Conference Call for First Quarter 2013 Financial Results

DUBLIN, Ireland, May 1, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that it will issue its first quarter 2013 financial results prior to the market opening on Friday, May 10, 2013.

Warner Chilcott

Warner Chilcott Announces FDA Approval of New Oral Contraceptive

DUBLIN, Ireland, April 22, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that the United States Food and Drug Administration (FDA) has approved MINASTRIN

Warner Chilcott

Warner Chilcott Announces FDA Approval of DORYX(R) Delayed-Release 200 mg Tablets

DUBLIN, Ireland, April 12, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that the United States Food and Drug Administration (FDA) has approved a 200 mg strength of DORYX® (doxycycline hyclate) Delayed-Release Tablets. DORYX Delayed-Release Tablets are a tetracycline-class oral antibiotic. The Company anticipates that it will commercially launch DORYX Delayed-Release 200 mg Tablets in July 2013.